Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Plan Includes No Increase For CDRH In 2014; User Fee Sequester Unresolved

This article was originally published in The Gray Sheet

Executive Summary

A House subcommittee passed an appropriations package last week that would keep FDA device funding levels flat in fiscal 2014. The package would increase appropriations to FDA as a whole compared to 2013, but it falls short of the President’s budget request, and leaves unresolved whether 2014 user fees would be sequestered.

You may also be interested in...



Hamburg Wants Predictability In FDA Funding, Ability To Access Sequestered User Fees

FDA commissioner says the agency cannot operate effectively without predictable budgets and that sequestering user fees needs to end.

News Briefs: User Fee Bill, Sunshine Mobile Apps, More

The House introduced a bill that would exempt device and drug user fees from sequestration cuts. CMS releases two mobile apps to help track payments required under the Sunshine law. More news.

Senate Approps Bill Seeks More Funds For FDA Than House

The FDA device funding approved by the Senate Committee is about $8 million more than the total OK’d by the House Appropriations Committee earlier this month, but neither legislation protects industry user fees from sequestration.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel